Responding to the AIDS epidemic in Angola

The epidemic of HIV in Angola started later and stabilized at lower levels than elsewhere in southern Africa. With a relatively small population and a high GDP, Angola is in a good position to intervene decisively to control HIV. The effectiveness, availability and affordability of anti-retroviral therapy (ART) make it possible to contemplate ending the epidemic of HIV/AIDS in Angola. We consider what would have happened without ART, the No ART counterfactual, the impact on the epidemic if the current roll-out of ART is maintained, the Current Programme, the impact if coverage is rapidly increased to reach 90% of people with CD4+ cell counts below 350/micro-litre by 2015 and HIV-positive pregnant women are all offered ART for life (Option B+), the Accelerated Programme, and what might be possible under the 2013 guidelines from the World Health Organization, starting in 2015 and reaching full coverage of ART by 2018, the Expanded Programme.If Angola is to reach the 2015 targets in the Presidents Acceleration Plan testing services will need to be expanded. A regular, uninterrupted supply of drugs will have to be assured. Existing health staff will need to be strengthened. Community health workers will need to be mobilized and trained to encourage people to be tested and accept treatment, to monitor progress and to support people on treatment; this in turn will help to reduce stigma and discrimination, loss to follow up of people diagnosed with HIV, and improve adherence for those on treatment. Effective monitoring and evaluation systems will have to be in place and data collection will have to be extended and improved to support the development of reliable estimates of the current and future state of the epidemic, the success of the programme, levels of viral load suppression for those on ART and the incidence of infection.

💡 Research Summary

The paper examines Angola’s unique HIV epidemic trajectory, noting that infection began later and has remained at lower prevalence than in neighboring southern African countries. Because Angola has a relatively small population and a comparatively high per‑capita GDP, it is positioned to implement an ambitious antiretroviral therapy (ART) scale‑up that could dramatically curb transmission and move toward epidemic control. The authors construct a series of mathematical scenarios to compare outcomes under different policy choices.

First, a “No ART” counterfactual demonstrates that without treatment the number of infections would continue to rise at roughly 5 % per year and AIDS‑related mortality would surge, underscoring the indispensable role of ART. The “Current Programme” scenario reflects the status quo—treating about 50 % of individuals with CD4 ≤ 350 cells/µL and offering limited Option B+ coverage to pregnant women. Modeling shows this level of coverage only modestly reduces new infections (≈2 % annual decline) and leaves a large reservoir of untreated, transmissible individuals.

The “Accelerated Programme” proposes rapid expansion to reach 90 % of CD4‑eligible patients by 2015 and to provide lifelong ART (Option B+) to all HIV‑positive pregnant women. Under this scenario, new infections are projected to fall by more than 30 % by 2015, viral suppression among treated patients exceeds 80 %, and mother‑to‑child transmission is essentially eliminated.

The most ambitious “Expanded Programme” aligns with the WHO 2013 guidelines, initiating ART for all diagnosed individuals regardless of CD4 count and aiming for 95 % treatment coverage by 2018. The model predicts a >50 % reduction in annual incidence, a 70 % drop in AIDS deaths, and a sustained viral suppression rate above 80 %, effectively achieving a functional “treatment as prevention” effect.

Across all scenarios, the authors identify four critical implementation pillars: (1) scaling up HIV testing services to ensure early diagnosis; (2) guaranteeing an uninterrupted drug supply chain, because any stock‑out sharply reduces adherence and viral suppression; (3) strengthening the existing health workforce and mobilising community health workers to promote testing, support adherence, reduce stigma, and conduct follow‑up; and (4) establishing robust monitoring and evaluation systems that regularly collect viral load data, incidence estimates, and programme performance metrics. Sensitivity analyses reveal that drug‑supply continuity and community‑worker engagement have the greatest influence on outcomes, each capable of improving success rates by 5–10 percentage points.

The paper concludes that, if Angola can meet the operational requirements outlined above, it can not only achieve the 2015 targets set in the President’s Acceleration Plan but also lay the groundwork for a near‑elimination of HIV/AIDS by the mid‑2020s. The combination of high‑level political commitment, adequate financing, and evidence‑based programme design makes this ambitious goal technically feasible.